Biotech News

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharmaceuticals (BCRX)ir.biocryst.com2026-05-27 19:03 ESTCompany update

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

BCRXBioCryst Pharmaceuticals2026-06-12 07:08:54 EST

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BCRXBioCryst Pharmaceuticals2026-05-13 15:10:46 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BCRXBioCryst Pharmaceuticals2026-05-06 18:52:16 EST

BioCryst to Present at Upcoming Investor Conference

BCRXBioCryst Pharmaceuticals2026-05-06 18:52:15 EST

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States